Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Leukemia evolving from paroxysmal nocturnal hemoglobinuria.

Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon S, Nagata Y, Patel BJ, Carraway HE, Sekeres MA, Maciejewski JP, Visconte V.

Leukemia. 2019 Aug 20. doi: 10.1038/s41375-019-0555-0. [Epub ahead of print] No abstract available.

PMID:
31431736
2.

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine.

Nawrocki ST, Han Y, Visconte V, Przychodzen B, Espitia CM, Phillips J, Anwer F, Advani A, Carraway HE, Kelly KR, Sekeres MA, Maciejewski JP, Carew JS.

Leukemia. 2019 Jul 29. doi: 10.1038/s41375-019-0529-2. [Epub ahead of print] No abstract available.

PMID:
31358855
3.

Distinct clinical and biological implications of CUX1 in myeloid neoplasms.

Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP.

Blood Adv. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423.

4.

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.

Carew JS, Espitia CM, Zhao W, Visconte V, Anwer F, Kelly KR, Nawrocki ST.

Blood Adv. 2019 Apr 23;3(8):1318-1329. doi: 10.1182/bloodadvances.2018026484.

5.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Advani AS, Cooper B, Visconte V, Elson P, Chan R, Carew J, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, Maciejewski J, Unger A, Kalaycio M, de Lima M, Sekeres MA.

Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.

PMID:
30992301
6.

Subclonal STAT3 mutations solidify clonal dominance.

Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, Visconte V, Lichtin AE, Mustjoki S, Radivoyevitch T, Sekeres MA, Maciejewski JP.

Blood Adv. 2019 Mar 26;3(6):917-921. doi: 10.1182/bloodadvances.2018027862.

7.

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP.

Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216.

8.

The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult.

Xie Y, Visconte V, Duan L, Rogers HJ.

Blood Res. 2018 Jun;53(2):163-166. doi: 10.5045/br.2018.53.2.163. Epub 2018 Jun 25. No abstract available.

9.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
10.

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Palam LR, Mali RS, Ramdas B, Srivatsan SN, Visconte V, Tiu RV, Vanhaesebroeck B, Roers A, Gerbaulet A, Xu M, Janga SC, Takemoto CM, Paczesny S, Kapur R.

JCI Insight. 2018 Feb 22;3(4). pii: 94679. doi: 10.1172/jci.insight.94679. eCollection 2018 Feb 22.

11.

Rational management approach to pure red cell aplasia.

Balasubramanian SK, Sadaps M, Thota S, Aly M, Przychodzen BP, Hirsch CM, Visconte V, Radivoyevitch T, Maciejewski JP.

Haematologica. 2018 Feb;103(2):221-230. doi: 10.3324/haematol.2017.175810. Epub 2017 Dec 7.

12.

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP.

Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22. No abstract available.

PMID:
28935992
13.

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.

Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST.

Leukemia. 2018 Jan;32(1):230-233. doi: 10.1038/leu.2017.272. Epub 2017 Aug 23. No abstract available.

14.

Genomic determinants of chronic myelomonocytic leukemia.

Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP.

Leukemia. 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30.

PMID:
28555081
15.

Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).

Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ.

Int J Lab Hematol. 2017 Aug;39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.

PMID:
28318095
16.

Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis.

Carew JS, Espitia CM, Zhao W, Han Y, Visconte V, Phillips J, Nawrocki ST.

Clin Cancer Res. 2017 Jun 1;23(11):2869-2879. doi: 10.1158/1078-0432.CCR-16-1742. Epub 2016 Nov 23.

17.

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms.

Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Advani AS, Carraway HE, Sekeres MA, Maciejewski JP, Carew JS.

Leukemia. 2017 Feb;31(2):505-510. doi: 10.1038/leu.2016.295. Epub 2016 Oct 24. No abstract available.

18.

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.

Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong Liu H, Bolwell B, Maciejewski JP, Copelan E, Tiu RV.

Am J Hematol. 2016 Jun;91(4):406-9. doi: 10.1002/ajh.24306. Epub 2016 Mar 14.

19.

Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts.

Mangaru Z, Shetty S, Visconte V, Liu HD, Rogers HJ.

Am J Hematol. 2016 Jun;91(4):E273-4. doi: 10.1002/ajh.24289. No abstract available.

20.

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine.

Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS.

Leukemia. 2016 May;30(5):1190-4. doi: 10.1038/leu.2015.250. Epub 2015 Sep 15. No abstract available.

Supplemental Content

Loading ...
Support Center